VERITAC-2 Trial
-
VERITAC-2: Vepdegestrant Demonstrates Clinical Benefit in ESR1-Mutated, ER+/HER2- Advanced Breast Cancer After Endocrine Therapy
Arvinas’ VERITAC-2 trial data, presented at ESMO 2025, showed vepdegestrant significantly delayed deterioration in quality of life, pain, and functionality compared to fulvestrant in ESR1-mutated ER+/HER2- advanced breast cancer patients. The trial enrolled 624 patients, with 270 harboring ESR1 mutations. Progression-free survival improved statistically, and the market awaits overall survival data, the key secondary endpoint. Vepdegestrant is a PROTAC ER degrader being co-developed with Pfizer and has received FDA Fast Track designation.
